Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.45 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971756 | 0.94 | LMNA (0.63) | LMNAKCNH2AADATKDM4EALDH1A1 | |
| SCHEMBL969051 | 0.92 | LMNA (0.68) | LMNAKCNH2AADATKDM4EALDH1A1 | |
| SCHEMBL3965024 | 0.91 | LMNA (0.73) | LMNAKCNH2AADATKDM4EALDH1A1 | |
| SCHEMBL966483 | 0.91 | LMNA (0.73) | LMNAKCNH2AADATKDM4EALDH1A1 | |
| SCHEMBL3968764 | 0.91 | LMNA (0.73) | LMNAKCNH2AADATKDM4EALDH1A1 | |
| SCHEMBL3968769 | 0.91 | LMNA (0.73) | LMNAKCNH2AADATKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL967999 | 0.90 | LMNA (0.72) | LMNAKCNH2AADATKDM4EALDH1A1 | |
| Acetic Acid SCHEMBL3970329 | 0.90 | LMNA (0.71) | LMNAKCNH2AADATKDM4EALDH1A1 | |
| Acetic Acid SCHEMBL3970333 | 0.90 | LMNA (0.71) | LMNAKCNH2AADATKDM4EALDH1A1 | |
| SCHEMBL968300 | 0.87 | LMNA (0.56) | LMNAKCNH2AADATKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1993547-B1 | PRODRUGS OF BENZOQUINOLIZINE-2-CARBOXYLIC ACID | WOCKHARDT LTD (IN) | 2012-08-22 | — | — | EP | disclosed |
| US-7868173-B2 | Prodrugs of benzoquinolizine-2-carboxylic acid | WOCKHARDT LIMITED (IN) | 2011-01-11 | — | — | US | disclosed |
| EP-1993547-A2 | PRODRUGS OF BENZOQUINOLIZINE-2-CARBOXYLIC ACID | Wockhardt Limited (IN) | 2008-11-26 | — | — | EP | disclosed |
| US-20070219227-A1 | Prodrugs of benzoquinolizine-2-carboxylic acid | PATEL MAHESH V | 2007-09-20 | — | — | US | disclosed |
| WO-2007102061-A2 | PRODRUGS OF BENZOQUINOLIZINE-2-CARBOXYLIC ACID | WOCKHARDT LTD (IN) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219227-A1 | Prodrugs of benzoquinolizine-2-carboxylic acid | BCAT2, ALAD, BCAT1 | OPRM1 588/4885LMNA 3146/4885KCNH2 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.